GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases ...

commitment provided by Atlas to fund the Company´s operations until the end of June 2025 (the "Financing Commitment").

Over the past few months, we’ve been exploring how generative AI can transform trial preparation by analyzing complex litigation materials ...